Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
South Korea
· Delayed Price · Currency is KRW 161,400
-7,600 (-4.50%)
Jun 13, 2025, 3:30 PM KST
Sam Chun Dang Pharm. Revenue
Sam Chun Dang Pharm. had revenue of 50.62B KRW in the quarter ending March 31, 2025, with 4.46% growth. This brings the company's revenue in the last twelve months to 213.08B, up 8.18% year-over-year. In the year 2024, Sam Chun Dang Pharm. had annual revenue of 210.92B with 9.47% growth.
Revenue (ttm)
213.08B
Revenue Growth
+8.18%
P/S Ratio
17.62
Revenue / Employee
519.72M
Employees
410
Market Cap
3,753.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | 166.86B | -19.74B | -10.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |